Royalty Pharma plc (RPRX) Tops Q2 Revenue Estimate
Tweet
Share
E-mail
Get Alerts RPRX Hot Sheet
Price: $55.78 -0.52%
Financial Fact:
Loss per share - basic and diluted:: -0.17
Today's EPS Names:
CRMT, FOMI, FLES, More
Financial Fact:
Loss per share - basic and diluted:: -0.17
Today's EPS Names:
CRMT, FOMI, FLES, More
Join SI Premium – FREE
Royalty Pharma plc (NASDAQ: RPRX) reported Q2 cash receipts of $536 million versus the consensus estimate of $532.56 million.
GUIDANCE:
Royalty Pharma plc sees FY2022 adjusted cash receipts $2.275-2.35 billion, versus the consensus of $2.28 billion.
For earnings history and earnings-related data on Royalty Pharma plc (RPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
- AeroVironment (AVAV) Tops Q4 EPS by 36c
- American Eagle Outfitters names new CFO, reaffirms 2026 guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
